ArticleEuropean thyroid journal2026
Clinical presentation and outcomes of medullary thyroid cancer in two European countries: impact of diagnostic strategies.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate differences in clinical presentation, diagnostic and therapeutic modalities, and outcomes in two cohorts of patients with sporadic medullary thyroid carcinoma (MTC) from reference centres in Italy and the Netherlands. The two centres have different diagnostic approaches, including the use of routine calcitonin (CT) measurement. Methods: A total of 165 patients (106 Italian and 59 Dutch) were retrospectively included. The cohorts were compared overall and according to diagnostic modality. Logistic regression and multivariable Cox proportional hazards models were used, as appropriate, to assess progression-free survival (PFS), disease-specific survival (DSS) and associated risk factors. Results: The Dutch cohort presented with more advanced disease, as per higher TNM, AJCC staging, and significantly higher CT both preoperative and at last visit (P < 0.001). Dutch patients received more frequently second operations, radiotherapy, and systemic treatments. PFS and 10-year DSS were significantly lower in the Dutch cohort (P < 0.001 and P 0.01). Tumour size, nodal involvement, presence of distant metastases at diagnosis and progression during the follow-up were independent strong predictors of shorter PFS and DSS. Patients diagnosed via routine CT measurement showed a less aggressive presentation and more favourable outcome. Conclusion: We compared for the first time two MTC cohorts from countries with different diagnostic and therapeutic approaches. Our data contribute to highlighting an association between routine CT measurement and MTC presentation and outcome, while suggesting that caution should be exercised when interpreting the differences among countries in MTC prevalence and clinical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.